Maze Therapeutics, Inc. MAZE R2KR3KPHARMA
Company Overview
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.18.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%, earnings -351.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -351.04% |
Stock Price Performance
| 1 Year: | +92.72% |
| 6 Months: | -41.53% |
| 3 Months: | +7.99% |
| 1 Month: | -8.13% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.77 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 49.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MAZE Maze Therapeutics, Inc. R2KR3KPHARMA | 26.21 | -11.15 | $1.45B | 0.00% | -38.15% | -38.67% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 165.00M | 2.50M | - | 0 | - | 20.00M |
| Operating Income | -28.01M | 139.56M | -24.23M | -35.40M | -36.47M | -32.97M | -26.55M |
| Net Income | -32.49M | 139.06M | -24.75M | -32.79M | -33.68M | -30.09M | -24.21M |
| Diluted EPS | -13.91 | 3.22 | -10.25 | -1.15 | -0.77 | -0.66 | -0.45 |
| R&D Expense | 21.88M | 19.55M | 19.86M | 27.58M | 28.11M | 25.19M | 34.15M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167.50M | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 142.90M |
| Operating Income | -111.03M | -98.55M | 57.59M | -142.90M |
| EBITDA | -107.21M | -94.46M | 60.88M | -140.50M |
| Interest Expense | - | - | - | - |
| Pretax Income | -114.94M | -100.42M | 53.40M | -131.12M |
| Tax Provision | - | 0 | 1.17M | 0 |
| Net Income | -114.94M | -100.42M | 52.23M | -131.12M |
| Diluted EPS | -3.29 | -2.87 | 0.08 | -3.05 |
| R&D Expense | - | - | 83.50M | 108.45M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 240.54M | 397.13M |
| Total Equity | -373.85M | -311.18M | 354.97M |
| Cash & Equivalents | - | 196.81M | 189.25M |
| Total Liabilities | - | 43.64M | 42.16M |
| Current Liabilities | - | 20.67M | 22.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | 75.95M | -111.94M |
| Investing Cash Flow | -1.15M | -170.96M |
| Financing Cash Flow | 92.85M | 275.34M |
| Capital Expenditure | -1.15M | -794.00K |
| Free Cash Flow | 74.81M | -112.73M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | 34.4% | - |
| Net Margin % | - | - | 31.2% | - |
| ROE % | - | 26.9% | -16.8% | -36.9% |
| ROCE % | - | - | 26.2% | -38.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 9.06% | 5.03M | $138.10M |
| 2 | TRV GP IV, LLC | 8.05% | 4.47M | $122.77M |
| 3 | Arch Venture Management, Llc | 7.42% | 4.12M | $113.05M |
| 4 | Deep Track Capital, Lp | 6.72% | 3.73M | $102.42M |
| 5 | Blackrock Inc. | 6.31% | 3.50M | $96.12M |
| 6 | Jupiter Topco LLC | 6.14% | 3.41M | $93.52M |
| 7 | T. Rowe Price Investment Management, Inc. | 4.69% | 2.60M | $71.45M |
| 8 | Logos Global Management LP | 3.48% | 1.94M | $53.10M |
| 9 | Vanguard Capital Management LLC | 3.20% | 1.78M | $48.79M |
| 10 | a16z Capital Management, L.L.C. | 3.06% | 1.70M | $46.71M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MAZE
How MAZE Group (MAZE) Affects Rotational Strategy Timing - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQVXl1N3oxamxNZzZkZjNBa0FVTm9LTmdwWGZXNExJcUNPZEItbnhZMmxMaldMcW14RVBhZjB4LVgwTDk3NnVCbExQckpBdUNrTFBYSU9yN0xHQnNjUzdfZE5VSmFQY1BLcHJvLWRfUUNMU19LU2NjMUJpckhwMUV0bjdNZVY3c2Eyd2JfZl…
Maze Therapeutics (MAZE) CEO sells shares to cover taxes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxON25DT0FWNnhtVU82YUhLY29UZThsMDU1a1VZaHF2bVVnM1kyT1lZbm9NaWtQd3o5TnVqWXhWSE9XdFAwbGVxdHNsVWdDRzcyNVlFX3VVWS1wMDU1VTc4azNFUVkzVXJBQUpZZ0E4NnJxM0hSWXpuZWpUdld5RVNQTkkzbmY0Z1YtbFMxcD…
Don't Ignore The Insider Selling In Maze Therapeutics - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQcHd0dmQxYmp6MzE2T0lPaFlhcWY5Wmk4d3ZldlA1bnNCTmNkVjI4akZZQnpHREpQdEE1MldDUHJxaERHN25JZ293WHY0V2lCWHRPeEJSREhtMWprSVJVWEpUWnVVM1RrRGxFbExhT19DaHQ3ZW9aODN0UjIxWS04R2wwVC1NN1pST2lTVz…
Maze Therapeutics CSBO Dandekar divests $206,823 of common stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNNW1EN0p2SGNkcmZfUW5MMHFPM2pvT0R0X0h5TlM2Mk9ndm9BU2h1QnpPNGNpQy1kbUlQdDdUV09DTXFBY3U1WjVIS1FjSF9xSGhIZmNxZFlQRE1qaDBlenVFaGxucHN1bmY5SEpad1RqX2g4TE55aHF2UkF4OGY3bm9UQkdXR1ZiV3p1Z2…
After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets - Fierce Biotech
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNMFZSTTNRdXU5M2dzd0NpRVIzc18zaElPd0dQUngwZHN5SlRsV0FWRE9sd2Jka3RlX2psdlY5bmZtTHhYeVJJaHMzMUtQd21hblB3bmxFcmJkUEl5SmlPNGQ4cXF2MEFHemhIYXlpVmJhOG9jS1R1eEpoM1M3SHQ4OS16dzBzU1NmSnZvUm…
$MAZE stock is down 10% today. Here's what we see in our data. | MAZE Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPVFJJUlhMa3lqM0pyTW93X0lPcnZTNU1CcXN3ZjlxcWhwc0t2czR0bTRjOTBLNktzVkJyQlp5SHNIOUR1NHhRY1JqM1ZuMXJCY3NFQ2d3dVRKb2Z5d1NIN0Vpci1yWHZnMDYxazBUN2stTnJITGhpOW42Y1FIUm5zZHYzV05zTUJvRDVSZU…
MAZE — Frequently Asked Questions
What is the current share price of Maze Therapeutics, Inc. (MAZE)?
As of 2026-09-07 16:24 PDT, Maze Therapeutics, Inc. (MAZE) trades at $26.21 on NasdaqGM. Its 52-week range is $13.23 to $51.84.
What is the market capitalisation of MAZE?
Maze Therapeutics, Inc. (MAZE) has a market capitalisation of $1.45B on NasdaqGM.
What is the P/E ratio of MAZE?
MAZE trades at a trailing price-to-earnings (P/E) ratio of -11.15. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.14.
What is the return on equity (ROE) of MAZE?
MAZE has a return on equity (ROE) of -38.67%. Its return on capital employed (ROCE) is -38.15%.
Is MAZE a good stock to buy?
This page provides a data-driven analysis of Maze Therapeutics, Inc. (MAZE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.